An assay based on gold nanoparticles could detect recurrences of prostate cancer sooner than is possible with existing techniques.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Freedland, S. J. & Moul, J. W. J. Urol. 177, 1985–1991 (2007).
Thaxton, C. S. et al. Proc. Natl Acad. Sci. USA 106, 18437–18442 (2009).
Barry, M. J. N. Engl. J. Med. 360, 1351–1354 (2009).
Healy, D. A. et al. Trends Biotechnol. 25, 125–131 (2007).
Thompson, I. M. et al. J. Natl Cancer Inst. 98, 529–534 (2006).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Hearty, S., Leonard, P. & O'Kennedy, R. Barcodes check out prostate cancer. Nature Nanotech 5, 9–10 (2010). https://doi.org/10.1038/nnano.2009.459
Issue Date:
DOI: https://doi.org/10.1038/nnano.2009.459
This article is cited by
-
DNA-framework-based multidimensional molecular classifiers for cancer diagnosis
Nature Nanotechnology (2023)
-
Aberrant PSA glycosylation—a sweet predictor of prostate cancer
Nature Reviews Urology (2013)